ACRS Stock — Aclaris Therapeutics Inc

Aclaris Therapeutics Inc (ACRS)

Updated October 16, 2026.

ACRS is a Stock. Total return is -70.3% over the past 11 years, 428.2 points behind SPY at 357.9%.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel molecules to treat immuno-inflammatory diseases, with a pipeline including monoclonal antibodies and kinase inhibitors in Phase 1b through Phase 2 trials for conditions such as atopic dermatitis, asthma, and autoimmune disorders. As an early-stage biotech company, it does not currently distribute to shareholders. This security appeals to investors seeking exposure to clinical-stage drug development with a longer time horizon and higher risk tolerance, rather than those seeking current income.

ACRS performance versus SPY

Price and return data through 2026-10-16.

Total return is -70.3% over the past 11 years, 428.2 points behind SPY at 357.9%. Over the past year its total return — price change plus distributions reinvested — is 60.0%. Its deepest 1-year drawdown was 49.8%.

ACRS key facts

Asset type

Stock

Asset class

Equity

Inception date

10/07/2015

Distribution frequency

None

Last close

$3.28 (as of 2026-10-16)

Market cap

$482,812,369

Average volume

2456112.0

Beta

0.882

Payout ratio

0.0%

EPS

$-0.58

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACRS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 49.8%.

Who may consider ACRS — and who may not

It is a weaker fit for investors who need monthly cash flow (ACRS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACRS

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions